Share This Page
Suppliers and packagers for generic pharmaceutical drug: CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; SODIUM CHLORIDE; SODIUM LACTATE
✉ Email this page to a colleague
CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; SODIUM CHLORIDE; SODIUM LACTATE
Listed suppliers include manufacturers, repackagers, relabelers, and private labeling entitities.
Suppliers and packagers for generic pharmaceutical drug: CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; SODIUM CHLORIDE; SODIUM LACTATE
Pharmaceutical Supplies: Suppliers for Calcium Chloride, Dextrose, Magnesium Chloride, Sodium Chloride, and Sodium Lactate (API and Injection-Grade)
Executive summary: Common IV electrolyte and glucose ingredients have a broad supplier base across US and EU. Competitive risk is driven less by patent exclusivity (most are commodity salts and mixtures) and more by GxP manufacturing capacity, DMF/CMC documentation availability, and facility-level compliance for sterility, endotoxin, and container-closure systems. For procurement, prioritize suppliers with injectable-grade production, readily transferable regulatory packages (US DMFs/EDMFs), and sustained commercial supply of both bulk drug substances and finished IV solutions (single-ingredient and multi-electrolyte formulations).
Which companies supply injectable-grade Calcium Chloride for IV use?
Featured snippet answer: Injectable calcium chloride is supplied by major sterile injectables manufacturers and bulk sterile solution producers, sourced either as drug substance (calcium chloride) under GMP or as finished IV injection solutions.
Common supply formats
- Calcium chloride (injection): typically for ICU resuscitation, hypocalcemia, and electrolyte replacement.
- Calcium chloride dihydrate: frequently used as the underlying salt in injection formulations.
- Bulk calcium chloride: used by finished-dose IV solution manufacturers.
Supplier categories
- Finished-dose sterile injectables plants
- Bulk chemical producers with GMP-controlled particle specs and trace metals
- Contract manufacturers producing sterile solutions under cGMP with validated sterilization and aseptic processing
Procurement checklist for calcium chloride
- Sterility assurance method (terminal sterilization vs aseptic)
- Endotoxin limits and LAL validation controls
- Container closure system compatibility (HDPE vs glass, rubber components)
- Trace impurities control (heavy metals, sulfate, carbonate)
- Batch release specs and COA turnaround time
Who supplies Dextrose injection (glucose) in the US and EU?
Featured snippet answer: Dextrose injection is supplied by large sterile injectables manufacturers with established production lines for D5W (5% dextrose) and higher concentrations (e.g., 10%/50% dextrose) and by API-grade glucose suppliers feeding finished-dose manufacturers.
Supply depends on concentration and intended use
- 5% dextrose in water (D5W): most common maintenance infusion.
- 10% dextrose: used for specific nutritional and glucose management needs.
- 50% dextrose (D50W): concentrated product for rapid correction protocols.
Supplier inclusion criteria
- Facility clearance for high-purity dextrose solutions
- GMP track record for sterile glucose solutions (particle counts, bioburden controls)
- Regulatory support for DMF/EDMF submissions (where applicable)
Operational note for sourcing
Dextrose is commodity-derived but injection-grade purity, sterility assurance, and container closure compliance are the differentiators. Buyers typically select suppliers based on history of supply continuity and regulatory package readiness.
Which manufacturers supply Magnesium Chloride injection for IV electrolyte replacement?
Featured snippet answer: Magnesium chloride is commonly sourced from injectables manufacturers producing sterile magnesium preparations and from GMP bulk chemical supply feeding sterile solution compounding or finished-dose production.
Formulation drivers
- Concentration targets (mg/mL magnesium content)
- Osmolality and compatibility with dextrose/saline infusion regimens
- Stability (pH control, precipitation prevention)
- Chloride load considerations for renal patients
Supplier selection
- Sterile processing capability (aseptic vs terminal)
- Tight specification controls on chloride content, sulfate, and related impurities
- Documentation for patient safety and batch traceability
Who supplies Sodium Chloride injection (normal saline) and bulk NaCl for IV?
Featured snippet answer: Sodium chloride injection and bulk sodium chloride are supplied broadly by both chemical producers and sterile injectables manufacturers. For procurement, finished-dose suppliers often dominate due to sterility and container-closure needs.
Common product lines
- 0.9% Sodium chloride injection (normal saline)
- Hypotonic saline variants (less commonly for routine infusion depending on protocol)
- Bulk sodium chloride for solution-makers (where regulatory strategy supports in-house fill or contract fill)
Selection factors
- Sterile filtration and endotoxin controls
- Particulate and subvisible particle compliance
- Bottle/bag ecosystem (glass vs plastic infusion containers)
Which companies supply Sodium Lactate injection and lactate salts?
Featured snippet answer: Sodium lactate is supplied as injection-grade sterile solutions and as lactate salts for finished-dose production, with procurement centered on purity, microbial limits, and stability.
Why supply matters
Sodium lactate products must meet consistent:
- Lactate concentration and optical/chemical purity
- Buffering performance in final formulation
- Stability under intended storage conditions
Supplier capability screening
- Stability indicating method package (for shelf-life)
- Sterility and endotoxin controls
- Compatibility data with IV container closure systems
Are these drugs patented, and does patent estate affect supplier availability?
Featured snippet answer: Calcium chloride, dextrose, magnesium chloride, sodium chloride, and sodium lactate are mostly commodity salts and glucose derived inputs used in generic or widely available injection solutions. Patent constraints are usually tied to specific finished formulations, container systems, manufacturing methods, or combination products, not the underlying salt itself.
What typically gets patented (when anything does)
- Method-of-manufacture for sterile solutions (process controls)
- Specific concentration ranges and stabilized formulations
- Fixed-dose combination IV products (electrolyte mixtures)
- Delivery system innovations (container and closure tech)
Procurement implication
Even when formulation IP exists, sourcing often shifts to:
- Alternative presentations (bags vs vials)
- Different strengths within pharmacopoeia range
- Equivalent sterile solution formats not covered by the same claims
What are the main regulatory documentation requirements when sourcing sterile injectables ingredients?
Featured snippet answer: Buyers normally require GMP-grade controls and, for US distribution, supplier packages that support FDA regulatory review where applicable.
Typical documents procurement teams request
- GMP certificates for sterile manufacturing sites
- CoA and batch release testing methods
- Stability data (for finished injectable solutions)
- DMF/EDMF status (where the supplier holds it and where buyers need it)
- Validation summary for sterilization, filtration, depyrogenation where used
How do suppliers usually structure product supply for these ingredients?
Featured snippet answer: Most supply is structured either as bulk drug substance (for a sterile solution manufacturer) or as a finished sterile injection ready for distribution.
Supply chain models
- Chemical producer → injectable solution manufacturer (bulk to fill)
- Sterile injectables manufacturer → distributor/hospital group contract
- Contract fill-finish provider → labeler/market authorization holder
Commercial risk points
- Sterile manufacturing capacity
- Container supply (glass, stoppers, bag films)
- Raw material volatility (commodity pricing for salts)
- Site regulatory inspection outcomes
What generic entry risks exist for these ingredient classes?
Featured snippet answer: For commodity electrolytes and dextrose, entry barriers come from sterile manufacturing compliance and documentation readiness, not core drug substance patents.
Where delays can still occur
- Container closure validation changes
- Sterility assurance validation gaps for a new line
- Scale-up changes requiring CMC updates
- Supplier switching friction (lead times, batch release timelines)
How to compare suppliers for these ingredients in RFP or vendor qualification
Featured snippet answer: Evaluate suppliers on regulatory readiness, sterility assurance, and supply continuity.
Comparison framework
| Supplier attribute | What to verify | Why it matters |
|---|---|---|
| Sterile manufacturing model | Aseptic vs terminal sterilization; filtration steps | Determines lot release risk and batch timelines |
| Endotoxin/bioburden controls | LAL method and acceptance limits; bioburden history | Patient safety compliance |
| Container-closure system | Compatibility and validation | Stability and particulate control |
| Regulatory package readiness | DMF/EDMF availability, CMC dossier quality | Speeds adoption and reduces CMC gaps |
| Supply continuity | Lead times, historical allocations | Avoids stockouts in infusion and ICU settings |
| Quality system maturity | CAPA turnaround, deviation frequency | Reduces batch rejection frequency |
| Batch traceability | Unique lot identification and recalls | Litigation and audit readiness |
Which supplier regions tend to be most reliable for US/EU procurement?
Featured snippet answer: Broadest reliable supply tends to come from established sterile injectables manufacturing hubs in the US, Western Europe, and regulated Asian GMP networks supplying finished injections or validated bulk.
Procurement strategy
- Dual-source critical SKUs (especially normal saline and concentrated dextrose)
- Keep at least one alternative container format qualified (bag vs vial)
- Pre-qualify secondary suppliers for sterility and endotoxin specs
Key Takeaways
- Calcium chloride, dextrose, magnesium chloride, sodium chloride, and sodium lactate are largely commodity-based inputs; supplier availability is driven more by sterile manufacturing capacity and regulatory documentation than by patent exclusivity.
- For procurement, prioritize suppliers that provide injectable-grade controls (sterility, endotoxin, particulate) and deliver regulatory package readiness (DMF/EDMF or equivalent CMC support).
- Supplier selection should be based on a repeatable scorecard: aseptic/terminal controls, container-closure compatibility, stability evidence, supply continuity, and quality system performance.
- For competitive and launch planning, IP risk is usually concentrated in specific finished formulations and combination products, not the underlying salts or dextrose.
FAQs
1) Can I source these ingredients as bulk drug substances instead of finished injections?
Yes, but adoption requires sterile solution manufacturing capacity (fill-finish) and a compatible regulatory pathway with validated CMC and sterility assurance.
2) What specs matter most for hospital procurement of normal saline and dextrose injections?
Endotoxin limits, sterility assurance, particulate control, container closure compatibility, and lot traceability.
3) How do container choices change supplier qualification for these IV products?
Container type affects leachables/extractables, stability, and particulate formation, so each system needs compatibility validation.
4) Do supplier changes create CMC risks even when the active ingredient is unchanged?
Yes. Differences in impurities profile, sterile processing parameters, and container closure can drive CMC updates and stability re-qualification.
5) What is the biggest operational risk when dual-sourcing these ingredients?
Supply continuity at the sterile manufacturing site and batch release throughput, not the raw material identity.
References
No sources were cited.
More… ↓
